1. A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma. (January 2017) Authors: Trusheim, John; Dunbar, Erin; Battiste, James; Iwamoto, Fabio; Mohile, Nimish; Damek, Denise; Bota, Daniela A; Connelly, Jennifer Journal: CNS oncology Issue: Volume 6:Number 1(2017) Page Start: 29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A tale of two multi‐focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone‐based OKN‐007. Issue 2 (14th December 2021) Authors: Zalles, Michelle; Smith, Nataliya; Saunders, Debra; Lerner, Megan; Fung, Kar‐Ming; Battiste, James; Towner, Rheal A. Journal: Journal of cellular and molecular medicine Issue: Volume 26:Issue 2(2022) Page Start: 570 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. ACTR-30. PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM). (5th November 2018) Authors: Shih, Kent; Schiff, David; Kim, Lyndon; Battiste, James; Campian, Jian; Puduvalli, Vinay; Wen, Patrick; Cloughesy, Timothy; van den Bent, Martin; Pirzkall, Andrea; Wood, Katie; Wei, Rachel; Du, Bing; Mu, Song; Ramakrishnan, Vanitha; Walbert, Tobias Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 6 Page Start: vi17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. ACTR-39. PAMIPARIB IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY (R/R) GLIOBLASTOMA (GBM); PHASE 1B/2 STUDY UPDATE. (11th November 2019) Authors: Piotrowski, Anna; Puduvalli, Vinay; Wen, Patrick; Campian, Jian; Colman, Howard; Pearlman, Michael; Butowski, Nicholas; Battiste, James; Glass, Jon; Cloughesy, Timothy; Schiff, David; van den Bent, Martin; Walbert, Tobias; Ahluwalia, Manmeet; Badruddoja, Michael; Kalra, Amandeep; Aregawi, Dawit; ... Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. ACTR-51. PHASE 2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF PI3K/MTOR INHIBITOR GDC-0084 GIVEN TO GLIOBLASTOMA (GBM) PATIENTS WITH UNMETHYLATED O6-METHYLGUANINE-METHYLTRANSFERASE PROMOTER STATUS. (5th November 2018) Authors: Wen, Patrick; Cloughesy, Timothy; de Groot, John; Battiste, James; Garner, James; Simpson, Jeremy; Olivero, Alan; Gerstner, Elizabeth Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 6 Page Start: vi23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. ACTR-64. PHASE 2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF PI3K/mTOR INHIBITOR GDC-0084 IN GBM PATIENTS WITH UNMETHYLATED O6-METHYLGUANINE-METHYLTRANSFERASE (MGMT) PROMOTER STATUS. (11th November 2019) Authors: Wen, Patrick; DeGroot, John; Battiste, James; Goldlust, Samuel; Garner, James; Simpson, Jeremy; Kijlstra, Jelle; Olivero, Alan; Cloughesy, Timothy Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options. (11th May 2017) Authors: Gay, Laurie M.; Kim, Sungeun; Fedorchak, Kyle; Kundranda, Madappa; Odia, Yazmin; Nangia, Chaitali; Battiste, James; Colon‐Otero, Gerardo; Powell, Steven; Russell, Jeffery; Elvin, Julia A.; Vergilio, Jo‐Anne; Suh, James; Ali, Siraj M.; Stephens, Philip J.; Miller, Vincent A.; Ross, Jeffrey S. Journal: Oncologist Issue: Volume 22:Number 7(2017) Page Start: 834 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options. (July 2017) Authors: Gay, Laurie M.; Kim, Sungeun; Fedorchak, Kyle; Kundranda, Madappa; Odia, Yazmin; Nangia, Chaitali; Battiste, James; Colon‐Otero, Gerardo; Powell, Steven; Russell, Jeffery; Elvin, Julia A.; Vergilio, Jo‐Anne; Suh, James; Ali, Siraj M.; Stephens, Philip J.; Miller, Vincent A.; Ross, Jeffrey S. Journal: Oncologist Issue: Volume 22:Number 7(2017) Page Start: 834 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. CTIM-06. CLINICAL EFFICACY AND BIOMARKER ASSESSMENT OF VT1021, A CD36/CD47 DUAL-TARGETING AGENT, IN RECURRENT GLIOBLASTOMA. (12th November 2021) Authors: Ahluwalia, Manmeet; Battiste, James; Bockorny, Bruno; Bullock, Andrea; Patel, Manish; Wen, Patrick; Shepard, Dale; Vaickus, Lou; Vincent, Melanie; Chen, Jian jenny; Wang, Suming; Watnick, Randolph; Crochiere, Marsha; Cieslewicz, Michael; Watnick, Jing Journal: Neuro-oncology Issue: Volume 23: Supplement 6(2021) Page Start: vi50 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. CTNI-16. FEASIBILITY PILOT STUDY OF OKN-007 IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE CHEMORADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. (9th November 2020) Authors: Battiste, James; Sung, Sarah; Wright, Deborah; Glenn, Chad; Algan, Ozer; Teague, April; Zhao, Yan; Cohoon, Andrew; Kim, Hyun Sook; Towner, Rheal Journal: Neuro-oncology Issue: Volume 22(2020)Supplement 2 Page Start: ii45 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗